BridgeBio Pharma And Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma
PALO ALTO, CA– December 1, 2020– BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Drugs & Pharmacology | Genetics | New Drug Applications | Pharmaceuticals